| Issue |
Med Sci (Paris)
Volume 39, Number 2, Février 2023
|
|
|---|---|---|
| Page(s) | 187 - 190 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/2023003 | |
| Published online | 17 February 2023 | |
Une thérapie très attendue… et un prix exorbitant !
Chroniques génomiques
A long-awaited - but prohibitively expensive - therapy
Biologiste, généticien et immunologiste, Président d’Aprogène (Association pour la promotion de la génomique), 13007 Marseille, France
Abstract
After many years of development, a gene therapy for haemophilia B has demonstrated effectiveness and durability, at least over a time span of three years. It has just been approved (as Hemgenix®) by the FDA in the USA and by the EMA in the EU. However, the multimillion price tag of this treatment is a serious problem for healthcare systems and for patients, and raises a number of thorny issues about marketing practices of the pharmaceutical industry.
© 2023 médecine/sciences – Inserm
Article publié sous les conditions définies par la licence Creative Commons Attribution License CC-BY (https://creativecommons.org/licenses/by/4.0), qui autorise sans restrictions l'utilisation, la diffusion, et la reproduction sur quelque support que ce soit, sous réserve de citation correcte de la publication originale.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.